You are here

FDA approval

Copaxone ®

Copaxone - as marketed by Teva Pharmaceuticals

The first innovative drug to be developed in Israel and to receive FDA approval, Copaxone® is a unique multiple sclerosis immunomodulator: the first and only non-interferon agent for the treatment of relapsing-remitting multiple sclerosis.  Copaxone® is licensed to Teva Pharmaceuticals Ltd.


Subscribe to FDA approval